Optimizing malarial treatment in HIV and kidney disease patients ( Optimahk trial)

Phase 4

Recruiting

• Conditions: HIV/AIDS; Malaria; Kidney Disease

• Registration Number: PACTR202308810518432
• Lead Sponsor: Dr. Abdulwasiu A Busari

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-18
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Age 18 years and older.

2. HIV positive

3. Fever (axillary temperature = 37.5°C), or history of fever in previous 48 hours;

4. Microscopic confirmation of asexual stages of P. falciparum or mixed infection or malaria parasite densities >2,000/?l

5. Receiving ART for at least 3 months.

6. Having CKD as evident by GFR <60 mL/min/1.73m2 and/or proteinuria

7. Willingness to give informed consent.

Exclusion Criteria

1. Pregnancy.

2. Severe/complicated malaria.

3.Severe anaemia (<8.5 g/dl haemoglobin (Hb));

4. Full course of AA or AL treatment or more than two doses of another antimalarial in the past four weeks.

5. Known hypersensitivity to artemisinin derivates, amodiaquine, artemether-lumefantrine, or raltegravir.

6. Patient on haemodialysis

7. Patient with a history of cardiac arrhythmias

8. Not willing to give informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified